Tuberculosis treatment and resulting abnormal blood glucose: a scoping review of studies from 1981-2021

Background Hyperglycaemia is a risk factor for tuberculosis. Evidence of changes in blood glucose levels during and after tuberculosis treatment is unclear. Objective To compile evidence of changes in blood glucose during and after tuberculosis treatment and the effects of elevated blood glucose changes on treatment outcomes in previously normoglycaemic patients. Methods Original research studies (1980 to 2021) were identified in PubMed, Web of Science, CINAHL and Embase databases. Results Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prospective. Fasting blood sugar was the most common clinical test (64%), followed by the glycated haemoglobin test and the oral glucose tolerance test (each 50%). Most tests were conducted at baseline and in the third month of treatment. Twelve studies showed that the prevalence of hyperglycaemia in previously normoglycaemic patients decreased from baseline to follow-up and end of treatment. Three studies showed successful treatment outcomes of 64%, 75% and 95%. Patients with hyperglycaemia at baseline were more likely to develop cavitary lung lesions and poor treatment outcomes and had higher post-treatment mortality. There was no difference in outcomes by human immunodeficiency virus (HIV) status. Conclusion Elevated blood glucose in normoglycaemic patients receiving treatment for tuberculosis decreased by the end of treatment. Positive HIV status did not affect glucose changes during treatment. Further research is needed to investigate post-treatment morbidity in patients with baseline hyperglycaemia and the effects of HIV on the association between blood glucose and tuberculosis.

Automated summary

This study compiled evidence of changes in blood glucose during and after tuberculosis treatment in previously normoglycaemic patients. It was found that elevated blood glucose in normoglycaemic patients decreased by the end of treatment. Patients with hyperglycaemia at baseline were more likely to develop cavitary lung lesions and experienced poor treatment outcomes and higher post-treatment mortality.